Integrity Alliance LLC. Invests $229,000 in Zimmer Biomet Holdings, Inc. $ZBH

Integrity Alliance LLC. purchased a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,027 shares of the medical equipment provider’s stock, valued at approximately $229,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janney Montgomery Scott LLC grew its stake in shares of Zimmer Biomet by 0.5% in the first quarter. Janney Montgomery Scott LLC now owns 25,647 shares of the medical equipment provider’s stock worth $2,903,000 after acquiring an additional 118 shares during the period. Curbstone Financial Management Corp grew its stake in shares of Zimmer Biomet by 3.4% in the first quarter. Curbstone Financial Management Corp now owns 4,266 shares of the medical equipment provider’s stock worth $483,000 after acquiring an additional 140 shares during the period. Brooklyn Investment Group grew its stake in shares of Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the period. Roberts Wealth Advisors LLC grew its stake in shares of Zimmer Biomet by 0.8% in the first quarter. Roberts Wealth Advisors LLC now owns 18,497 shares of the medical equipment provider’s stock worth $2,093,000 after acquiring an additional 152 shares during the period. Finally, Wesbanco Bank Inc. grew its stake in shares of Zimmer Biomet by 0.8% in the first quarter. Wesbanco Bank Inc. now owns 20,012 shares of the medical equipment provider’s stock worth $2,265,000 after acquiring an additional 163 shares during the period. Institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ZBH. UBS Group lifted their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research note on Friday, August 8th. Royal Bank Of Canada raised their price objective on shares of Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating on the stock in a report on Tuesday, July 8th. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Finally, Raymond James Financial raised their price objective on shares of Zimmer Biomet from $104.00 to $113.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Nine investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $111.00.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH opened at $103.15 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. Zimmer Biomet Holdings, Inc. has a 1-year low of $89.22 and a 1-year high of $114.72. The company has a market capitalization of $20.43 billion, a P/E ratio of 25.10, a P/E/G ratio of 2.40 and a beta of 0.68. The firm’s 50 day simple moving average is $99.46 and its two-hundred day simple moving average is $99.55.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.09. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.06 billion. During the same quarter in the previous year, the firm earned $2.01 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Insider Activity

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This trade represents a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.